Morgan Stanley Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Revance Therapeutics (NASDAQ:RVNC) and lowered the price target from $26 to $25.
August 09, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Revance Therapeutics and lowered the price target from $26 to $25.
The lowering of the price target by Morgan Stanley could potentially lead to a decrease in the stock price of Revance Therapeutics in the short term. This is because the new price target is lower than the previous one, indicating a less optimistic outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100